U.S. FDA says Evusheld may not protect against Omicron subvariant XBB.1.5
(Reuters) – The U.S. Food and Drug Administration said on Friday it does not expect AstraZeneca’s COVID-19 antibody cocktail Evusheld to provide protection against the Omicron subvariant XBB.1.5. The subvariant has been causing concern among scientists after its rapid spread in the United States in December. While the agency is awaiting additional data to verify …
U.S. FDA says Evusheld may not protect against Omicron subvariant XBB.1.5 Read More »









